Diabetes Dialogue: Celebrating 150 Episodes!

Welcome back to Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives!

In this milestone 150th episode of Diabetes Dialogue: Technology, Therapeutics, and Real-World Perspectives, hosts Diana Isaacs, PharmD, an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and co-director of Endocrine Disorders in Pregnancy at the Cleveland Clinic, and Natalie Bellini, DNP, program director of Diabetes Technology at University Hospitals Diabetes and Metabolic Care Center, reflect on 3 and a half years of transformation in diabetes care and the evolution of their podcast since its launch in early 2022.

What began as a modest plan for monthly discussions rapidly expanded into a weekly forum driven by an ever-accelerating pace of clinical innovation and the hosts’ shared enthusiasm for translating emerging science into practice.

Isaacs and Bellini revisit their earliest episode, which featured discussions on the then newly available implantable 180-day CGM and the Dexcom G7’s CE-mark approval—milestones that have since evolved into a landscape of year-long CGM systems and broader global access. They note how these conversations have paralleled major shifts across the therapeutic spectrum, including the rise of GLP-1 receptor agonists and dual incretin therapies, exemplified by tirzepatide and semaglutide, which have demonstrated benefits extending beyond glycemic control to encompass weight management, renal protection, MASH, and cardiovascular risk reduction.

Reflecting on some of their most popular episodes, the hosts emphasize the significance of the discussion with Timothy Garvey, MD, on the future of incretin therapies—one that accurately anticipated the widespread adoption and subsequent shortages of these agents. They also highlight their recurring Standards of Care update episodes, which distill extensive guideline revisions into clinically actionable insights. Drawing from their dual roles as practicing clinicians and contributors to these guidelines, Isaacs and Bellini underscore the importance of bridging evidence with real-world applicability—ensuring that new data meaningfully influence patient outcomes.

The conversation expands to the remarkable progression of diabetes technology, including episodes featuring experts such as Alan Lotvin, MD, Laurel Messer, PhD, RN, and Robert Vigersky, MD, discussing next-generation insulin pumps, automated insulin delivery algorithms, and strategies for optimizing time in range. They recall early access interviews with leaders from Medtronic, Tandem, Beta Bionics, and Dexcom, highlighting the privilege of sharing breaking innovations directly with healthcare professionals. Coverage has also extended to landmark clinical trials such as CATALYST, FLOW, and INHALE, where firsthand discussions with investigators have illuminated how new therapies—from semaglutide’s kidney and cardiovascular benefits to inhaled insulin’s renewed clinical role—are reshaping contemporary practice.

Closing on a personal and celebratory note, Isaacs and Bellini express gratitude to their listeners and collaborators, recalling their journey from long-distance colleagues to near neighbors, friends, and co-educators. Looking ahead to upcoming meetings—including the Diabetes Technology Meeting, ADCES Technology Conference, and ATTD 2026 in Barcelona—they reaffirm their commitment to advancing evidence-based, patient-centered diabetes care through continued dialogue, discovery, and connection.